Survodutide vs Tirzepatide
Two different second hormones bolted onto GLP-1: tirzepatide adds GIP and is approved, survodutide adds glucagon and is investigational despite Phase 3 results.
Short answer
The clearest difference is regulatory. Tirzepatide is FDA-approved, and survodutide is still investigational in the US. Tirzepatide fits a reader who wants an FDA-approved product, while survodutide is marketed for weight loss and MASH. On the evidence, survodutide has human clinical data and tirzepatide has approval-level evidence.
Survodutide
A GLP-1/glucagon dual agonist in Phase 3 for both obesity and MASH; genuine placebo-controlled efficacy data in both indications, but no approval anywhere yet.
Full Survodutide evidence reviewTirzepatide
Zepbound / Mounjaro
Up to ~21% mean weight loss in SURMOUNT-1 — the most effective FDA-approved weight-management drug.
Full Tirzepatide evidence reviewSurvodutide vs Tirzepatide: head to head
- FDA status / approved use
Survodutide
Investigational; positive Phase 3 obesity and liver trials, not yet approved anywhereTirzepatide
Prescription drug sold as Mounjaro and Zepbound- Marketed for
Survodutide
Weight loss, MASHTirzepatide
Weight loss, type-2 diabetes- Outcome areas
Survodutide
Weight loss / appetite; Liver / detoxTirzepatide
Weight loss / appetite; Blood sugar / insulin sensitivity- Evidence grade
Survodutide
Clinical dataTirzepatide
FDA-approved- How it works
Survodutide
Activates GLP-1 and glucagon receptors to curb appetite and raise energy expenditureTirzepatide
Dual agonist of the GLP-1 and GIP receptors- Route and dosing
Survodutide
Subcutaneous injection, once weeklyTirzepatide
Subcutaneous, once weekly (Zepbound label); maintenance 5, 10 or 15 mg once weekly (10 or 15 mg for sleep apnea)- Headline human result
Survodutide
Mean weight change about −16.6% vs −3.2% on placebo at 76 weeks in the 2026 Phase 3 SYNCHRONIZE-1 trialTirzepatide
20.9% mean weight loss vs 3.1% on placebo at 72 weeks (SURMOUNT-1, 15 mg weekly)- Strongest evidence
Survodutide
Phase 2 obesity RCT, 2024Survodutide evidence reviewPubMed 38330987Tirzepatide
SURMOUNT-1, NEJM 2022Tirzepatide evidence reviewPubMed 35658024- Key safety signal
Survodutide
Common, dose-related nausea, diarrhea and vomitingTirzepatide
Gastrointestinal side effects, the same class as semaglutide- How it is obtained
Survodutide
Legitimately available only inside clinical trials; vials sold online are gray-market research chemicalsTirzepatide
Prescription. Manufacturer self-pay for Zepbound runs $299–$449 per fill, against a $1,086 list priceZepbound cost breakdown
| Survodutide | Tirzepatide | |
|---|---|---|
| FDA status / approved use | Investigational; positive Phase 3 obesity and liver trials, not yet approved anywhere | Prescription drug sold as Mounjaro and Zepbound |
| Marketed for | Weight loss, MASH | Weight loss, type-2 diabetes |
| Outcome areas | Weight loss / appetite; Liver / detox | Weight loss / appetite; Blood sugar / insulin sensitivity |
| Evidence grade | Clinical data | FDA-approved |
| How it works | Activates GLP-1 and glucagon receptors to curb appetite and raise energy expenditure | Dual agonist of the GLP-1 and GIP receptors |
| Route and dosing | Subcutaneous injection, once weekly | Subcutaneous, once weekly (Zepbound label); maintenance 5, 10 or 15 mg once weekly (10 or 15 mg for sleep apnea) |
| Headline human result | Mean weight change about −16.6% vs −3.2% on placebo at 76 weeks in the 2026 Phase 3 SYNCHRONIZE-1 trial | 20.9% mean weight loss vs 3.1% on placebo at 72 weeks (SURMOUNT-1, 15 mg weekly) |
| Strongest evidence | Phase 2 obesity RCT, 2024Survodutide evidence reviewPubMed 38330987 | SURMOUNT-1, NEJM 2022Tirzepatide evidence reviewPubMed 35658024 |
| Key safety signal | Common, dose-related nausea, diarrhea and vomiting | Gastrointestinal side effects, the same class as semaglutide |
| How it is obtained | Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals | Prescription. Manufacturer self-pay for Zepbound runs $299–$449 per fill, against a $1,086 list priceZepbound cost breakdown |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- FDA-approved:
- Approved by the FDA for a defined indication, on the strength of pivotal human trials.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Tirzepatide is both the more effective option and the only one of the two anyone can be prescribed — SURMOUNT-1 reported up to about 21% mean weight loss, the largest figure for any FDA-approved weight-management drug. Survodutide’s Phase 3 SYNCHRONIZE-1 reported about −16.6% over 76 weeks, a genuine result but a smaller one, and the two were never compared head to head. The mechanistic difference is the actual point of the comparison: survodutide’s glucagon-receptor arm is intended to raise energy expenditure and mobilise hepatic fat, which is why its liver data stand out — SYNCHRONIZE-MASLD reported 84.2% of participants cutting liver fat by at least 30%. That is a different target from tirzepatide’s GIP plus GLP-1 combination, so these are not simply stronger and weaker versions of one idea.
Survodutide fits if
You are following glucagon agonism, particularly for liver outcomes, and are tracking a drug not yet approved anywhere.
Tirzepatide fits if
You want the most effective approved weight-management medicine available today.
Survodutide vs Tirzepatide: common questions
- Is tirzepatide FDA-approved but survodutide not?
- Yes. Tirzepatide is a prescription drug sold as Mounjaro and Zepbound. Survodutide is investigational; positive Phase 3 obesity and liver trials, not yet approved anywhere.
- Which has stronger human evidence, survodutide or tirzepatide?
- Tirzepatide. It has approval-level evidence (key source: SURMOUNT-1, NEJM 2022), while survodutide has human clinical data (key source: Phase 2 obesity RCT, 2024).
- What are the main safety concerns with survodutide and tirzepatide?
- For survodutide, watch for common, dose-related nausea, diarrhea and vomiting. For tirzepatide, watch for gastrointestinal side effects, the same class as semaglutide.
Key studies behind each
Survodutide
- le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. PubMed 38330987
- Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, et al. (2024). A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. PubMed 38847460
Tirzepatide
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PubMed 33567185
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PubMed 35658024
- Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. PubMed 34170647
- Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PubMed 40353578
The full evidence reviews
- Survodutide (BI 456906): the GLP-1 / glucagon dual agonist and its Phase 2 and Phase 3 data
An investigational dual agonist that adds glucagon to GLP-1 — with Phase 2 signals now confirmed in published Phase 3 trials: about 16.6% weight loss and strong liver-fat results. A straight read of the evidence and its limits.
Updated August 2026
- Tirzepatide vs semaglutide for weight loss: what the trials actually support
Most comparisons are cross-trial. Only SURPASS-2 and SURMOUNT-5 randomized one drug against the other — here's the precise distinction.
Updated August 2026